Seelos Therapeutics Inc (SEEL)
0.5401
-0.18
(-24.99%)
USD |
OTCM |
Nov 15, 16:00
Seelos Therapeutics Research and Development Expense (TTM): 20.43M for June 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2024 | 20.43M |
| March 31, 2024 | 27.97M |
| December 31, 2023 | 30.12M |
| September 30, 2023 | 39.70M |
| June 30, 2023 | 44.43M |
| March 31, 2023 | 54.28M |
| December 31, 2022 | 58.62M |
| September 30, 2022 | 62.66M |
| June 30, 2022 | 56.59M |
| March 31, 2022 | 42.55M |
| December 31, 2021 | 46.65M |
| September 30, 2021 | 30.94M |
| June 30, 2021 | 24.27M |
| March 31, 2021 | 21.40M |
| December 31, 2020 | 10.98M |
| September 30, 2020 | 16.35M |
| June 30, 2020 | 16.98M |
| March 31, 2020 | 17.24M |
| December 31, 2019 | 22.56M |
| September 30, 2019 | 14.16M |
| June 30, 2019 | 11.69M |
| March 31, 2019 | 10.15M |
| December 31, 2018 | 1.349M |
| September 30, 2018 | 0.788M |
| June 30, 2018 | 2.576M |
| Date | Value |
|---|---|
| March 31, 2018 | 3.253M |
| December 31, 2017 | 3.448M |
| September 30, 2017 | 3.817M |
| June 30, 2017 | 2.027M |
| March 31, 2017 | 3.691M |
| December 31, 2016 | 5.881M |
| September 30, 2016 | 8.938M |
| June 30, 2016 | 13.38M |
| March 31, 2016 | 13.98M |
| December 31, 2015 | 14.65M |
| September 30, 2015 | 26.85M |
| June 30, 2015 | 24.12M |
| March 31, 2015 | 23.11M |
| December 31, 2014 | 21.29M |
| September 30, 2014 | 6.679M |
| June 30, 2014 | 5.722M |
| March 31, 2014 | 5.154M |
| December 31, 2013 | 5.123M |
| September 30, 2013 | 5.033M |
| June 30, 2013 | 6.113M |
| March 31, 2013 | 5.611M |
| December 31, 2012 | 5.375M |
| September 30, 2012 | 6.336M |
| June 30, 2012 | 4.959M |
| March 31, 2012 | 5.898M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
10.98M
Minimum
Dec 2020
62.66M
Maximum
Sep 2022
33.93M
Average
30.12M
Median
Dec 2023
Research and Development Expense (TTM) Benchmarks
| Cassava Sciences Inc | 67.84M |
| Cara Therapeutics Inc | 85.14M |
| Citius Pharmaceuticals Inc | 11.87M |
| Moleculin Biotech Inc | 19.91M |
| 180 Life Sciences Corp | 2.226M |